08:25 AM EDT, 08/18/2025 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) shares were up over 11% premarket Monday after the company said its Allocetra cell therapy demonstrated improvements in a phase IIa trial in patients with moderate-to-severe knee osteoarthritis.

The Allocetra treatment arm showed a 24% reduction in knee pain and a 26% improvement in knee function compared with placebo, Enlivex said.

The biotechnology company said Allocetra demonstrated a favorable safety profile with no severe adverse events reported.